8-K: Astrana Health Reports Strong 2024 Results, Revenue Up 47% to $2.03 Billion

Astrana Health announces its fourth quarter and year-end 2024 financial results, highlighting significant revenue growth and strategic expansions.

Summary

• Astrana Health reported its financial results for the three and twelve months ended December 31, 2024.
• Total revenue for 2024 reached $2,034.5 million, a 47% increase from $1,386.7 million in 2023.
• Care Partners revenue increased by 52% to $1,949.0 million.
• Net income attributable to Astrana was $43.1 million, compared to $60.7 million in the previous year.
• Diluted earnings per share (EPS) were $0.90, down from $1.29 per share.
• Adjusted EBITDA rose by 16% to $170.4 million.
• For the fourth quarter of 2024, total revenue was $665.2 million, an 88% increase year-over-year.
• Care Partners revenue for the quarter increased by 98% to $647.7 million.
• The company reported a net loss of $7.0 million for the quarter, compared to a net income of $12.4 million in the same period last year.
• Adjusted EBITDA for the quarter increased by 21% to $35.0 million.
• Astrana Health expects total revenue between $2.5 billion and $2.7 billion and Adjusted EBITDA between $170 million and $190 million for 2025.
• The 2025 guidance includes approximately $15 million in strategic investments in automation and AI, as well as integration costs associated with planned acquisitions.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue growth is strong, the decrease in net income and EPS tempers the overall outlook. The company's strategic initiatives and future guidance provide some optimism.

Positives

• Significant revenue growth of 47% year-over-year, reaching $2,034.5 million.
• Adjusted EBITDA increased by 16% to $170.4 million.
• Strategic Care Enablement partnership with Provider HealthLink expands market reach.
• Successful amendment of credit agreement provides financial flexibility.
• Recognition of affiliates in the 2024 Standards of Excellence survey highlights quality of care.
• Stock repurchase demonstrates confidence in the company's value.
• Positive outlook for 2025 with projected revenue growth and stable Adjusted EBITDA.
• Increasing alignment through total cost of care responsibility in value-based arrangements with 73% of total capitation revenue from full risk.

Negatives

• Net income attributable to Astrana decreased from $60.7 million to $43.1 million.
• Earnings per share (EPS) diluted decreased from $1.29 to $0.90.
• Net loss attributable to Astrana for the fourth quarter of 2024 was $7.0 million, compared to a net income of $12.4 million in the same quarter of 2023.

Risks

• The company's forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially.
• The 2025 guidance includes approximately $15 million in strategic investments in automation and AI, as well as integration costs associated with planned acquisitions, which may impact profitability.
• There is no assurance that actual amounts will not be materially higher or lower than the provided expectations.

Future Outlook

Astrana Health projects total revenue between $2.5 billion and $2.7 billion and Adjusted EBITDA between $170 million and $190 million for the year ending December 31, 2025. This guidance includes approximately $15 million in expected costs associated with continued strategic investments in automation and AI, as well as ongoing and expected integration costs associated with planned acquisitions, but does not include contributions from any acquisitions which have not yet closed.

Management Comments

• Astrana Health's strong performance in 2024 highlights the strength of our patient-centered, payer-agnostic platform and our unwavering commitment to delivering high-quality, accessible care, said President and CEO of Astrana, Brandon K. Sim.
• Looking ahead, we remain focused on growing membership sustainably, further improving quality of care for our membership while responsibly managing costs, growing the 73% of our capitated revenue that now comes from full-risk arrangements, and driving operating leverage and integration of recently acquired assets.
• We are confident that our platform, combined with our proven ability to navigate industry headwinds and a favorable outlook on future reimbursement rates, will continue delivering sustainable, long-term value for all our stakeholders patients, physicians, providers, payers, and shareholders.

Industry Context

Astrana Health's focus on value-based care and technology-powered healthcare aligns with the broader industry trend towards improving patient outcomes and managing costs. The company's expansion into new markets and strategic acquisitions reflect a competitive landscape where healthcare providers are seeking to increase their scale and geographic reach.

Comparison to Industry Standards

• Astrana Health's revenue growth of 47% significantly outpaces the average growth rate for healthcare providers, which is typically in the single digits.
• The company's Adjusted EBITDA margin of 8% is comparable to other managed care organizations, such as UnitedHealth Group and Humana, but there is room for improvement to reach industry leaders with margins above 10%.
• The focus on full-risk arrangements aligns with the industry's shift towards value-based care, similar to companies like Oak Street Health and ChenMed, which specialize in full-risk primary care for seniors.
• The investment in automation and AI is in line with industry trends, as companies like Optum and Cerner are also investing heavily in technology to improve efficiency and patient care.

Related Party Transactions

• The Company repurchased 300,000 shares of the Company's common stock from Allied Physicians of California (APC), pursuant to a stock repurchase agreement, for an aggregate purchase price of approximately $10.6 million.

Stakeholder Impact

• Shareholders can expect continued revenue growth, but should be aware of the decreased net income and EPS.
• Patients should benefit from the company's focus on value-based care and improved quality of care.
• Providers in the Astrana network can expect increased support and resources through the Care Enablement platform.
• Payers may see improved cost management and patient outcomes through Astrana's integrated healthcare model.

Next Steps

• Onboarding Provider HealthLink onto Astrana's Care Enablement platform in the first half of 2025.
• Substantially completing the integration of Collaborative Health Systems acquisition by April 2025.
• Closing the proposed acquisition of Prospect Health.
• Continuing investments in automation and AI to yield at least $10 million in annual operating efficiencies by early 2026.

Key Dates